OUR BLOG
Insights
-
Digital R&D Solutions for a Safe and Productive Return to the Lab
As COVID lockdowns end, scientists returning to the lab face new challenges. Digital R&D technology such as software and lab automation offer solutions.
-
Four Key Principles We’re Using to Navigate COVID-19
In this article, our CEO, Liran Belenzon, discusses four key principles we at BenchSci are using to navigate through our new COVID-19 reality.
-
Overcoming the Gremlins of Burnout
Learn about the four stages of burnout and how to address them from Dr. Kari Sulenes, BenchSci’s on-site Professional Psychologist.
-
BenchSci Named a Great Place to Work and a Best Workplace for Startups
We are proud to be certified as a Great Place to Work! Read on to find out the various perks and health initiatives that made BenchSci a Best Workplace for start-up
-
Our Response to COVID-19: Publishing AI-Derived Experimental Data and Reagent Insights for COVID-19 R&D Efforts
To assist with the global R&D efforts for COVID-19, we’re collecting, processing, and documenting all new SARS-CoV-2 publication data and reagents, and making the data publicly available
-
9 Artificial Intelligence in Drug Discovery Trends and Statistics
Provides analysis of artificial intelligence in drug discovery data, including startup growth and funding.
-
15 Innovative Immunoassay Technologies to Help You Conduct Your Experiments Faster, High-throughput, with Less Sample, and Get Better Results
New technologies are flipping traditional antibody-based assays on their heads. These immunoassays are quicker, more sensitive, can be conducted high-throughput, and require minimal sample. It’s an exciting time to be a bench scientist!
-
A Step-wise Guide for Successful Antibody Search
Finding reliable antibodies that work well in an experiment usually requires a little trial and error at your end but there are some steps you can take to avoid the loss of money, time, and effort.
-
The Top 7 Monoclonal Antibody Drugs in 2024 will Target Inflammation and Cancer
Biologics are on the rise!
This article reviews the 7 monoclonal antibodies that are expected to be the best-selling antibody-based drugs in 2024, which focus on inflammation and cancer therapies.